Olivier Biondi
26
Documents
Publications
Exercise-specific effects on the motor performance, glycemia regulation and muscle histology of a mouse model of limb-girdle muscular dystrophy r1 (calpainopathy)20èmes journées de la Société Française de Myologie, Nov 2023, La Baule (France), France
Poster de conférence
hal-04496479v1
|
|
Exercise-specific effects on the motor performance, glycemia regulation and muscle histology of a mouse model of limb-girdle muscular dystrophy r1 (calpainopathy)28th annual congress of European College of Sport Science, Jul 2023, Paris, France
Poster de conférence
hal-04496489v1
|
|
In vivo effects of Sarconeos (API BIO101) on a mouse model of severe spinal muscular atrophyWorld Muscle Society 2021 Virtual Congress, Sep 2021, Paris, France
Poster de conférence
hal-04496236v1
|
The metabolism of skeletal muscle as a determinant for designing precision exercise in type 2 diabetes mellitusInnovation thérapeutique : Quels enjeux pour le développement des thérapies combinatoires ?, Université d'Evry; Genopole, Jun 2023, Evry, France
Communication dans un congrès
hal-04495968v1
|
|
Combination of antisense oligonucleotide therapy with BIO101 demonstrates synergistic beneficial effects in severe SMA-like mice3èmes International Scientific Congress on SMA, SMA Europe, Oct 2022, Barcelone (ES), Spain
Communication dans un congrès
hal-04496200v1
|
|
Combination of antisense oligonucleotide therapy with BIO101 demonstrates synergistic beneficial effects in severe SMA-like mice17èmes International Congress on Neuromuscular Disease, Jul 2022, Bruxelles (BEL), Belgium
Communication dans un congrès
hal-04496142v1
|
|
Combination of antisense oligonucleotide therapy with BIO101 demonstrates synergistic beneficial effects in severe SMA-like miceMyology 2022, Sep 2022, Nice, France
Communication dans un congrès
hal-04496181v1
|
|
Combinatory therapeutic innovation for Spinal Muscular AtrophyInnovative, combinatory therapies for neuromuscular diseases, Genopole; Université d'Evry, May 2022, Evry, France
Communication dans un congrès
hal-04495948v1
|
|
Combination of antisense oligonucleotide therapy with BIO101 demonstrates synergistic beneficial effects in severe SMA-like miceAnnual SMA research & Clinical Care Meeting, Jul 2022, Anaheim (CA), United States
Communication dans un congrès
hal-04496110v1
|
|
L'intensité de l'effort, un élément clef des effets de l'exercice dans la SMA ?33èmes Entretiens Annuels de la Fondation Garches, Fondation Garches, Nov 2021, Boulogne-Billancourt, France
Communication dans un congrès
hal-04495959v1
|
|
Sarconeos (API BIO101) improves outcomes in a mouse model of severe spinal muscular atrophy18èmes Journées de la Société Française de Myologie, SFM, Nov 2021, Saint-Etienne (FR), France
Communication dans un congrès
hal-04496219v1
|
|
Regular exercise prolongs survival in a type 2 SMA model mouse10th International Spinal Mucular Atrophy research Group Meeting, 10,11,12 juin 2006 Montréal, Canada, 2006, Canada
Communication dans un congrès
hal-00091129v1
|
Phytoecdysones and the derivatives thereof for use in the treatment of neuromuscular diseasesFrance, Patent n° : EP3937948A1. 2022
Brevet
hal-04496584v1
|
|
ERK inhibitors for use in treating spinal muscular atrophyFrance, Patent n° : 61/489,721. 2011
Brevet
hal-04496509v1
|